Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Renal AL Amyloidosis
NCT06420167Phase 2Recruiting
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in amyloid light chain amyloidosis, sponsored by Barbara Ann Karmanos Cancer Institute. Started Jul 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT06420167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420167.